{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T09:09:50Z","timestamp":1782551390961,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2012,11,23]],"date-time":"2012-11-23T00:00:00Z","timestamp":1353628800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1007\/s40263-012-0021-2","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T20:45:27Z","timestamp":1355777127000},"page":"1085-1096","source":"Crossref","is-referenced-by-count":53,"title":["Perampanel"],"prefix":"10.1007","volume":"26","author":[{"given":"Greg L.","family":"Plosker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,11,23]]},"reference":[{"key":"21_CR1","doi-asserted-by":"crossref","unstructured":"Neligan A, Hauser WA, Sander JW. The epidemiology of the epilepsies. Handb Clin Neurol. 2012;107(3rd series):113\u201333.","DOI":"10.1016\/B978-0-444-52898-8.00006-9"},{"key":"21_CR2","unstructured":"Figueroa Garcia A. Partial epilepsies. 2012. http:\/\/emedicine.medscape.com\/article\/1186635-overview . Accessed 2012 Sep 17 2012."},{"issue":"4","key":"21_CR3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","volume":"51","author":"AT Berg","year":"2010","unstructured":"Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005\u20132009. Epilepsia. 2010;51(4):676\u201385.","journal-title":"Epilepsia"},{"key":"21_CR4","unstructured":"The National Society for Epilepsy. Epilepsy: an introduction to epileptic seizures. 2012. http:\/\/www.epilepsysociety.org.uk\/AboutEpilepsy\/Whatisepilepsy\/Seizures . Accessed 17 Sep 2012."},{"issue":"11","key":"21_CR5","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2165\/11587900-000000000-00000","volume":"25","author":"E Perucca","year":"2011","unstructured":"Perucca E. The pharmacology of new antiepileptic drugs: does a novel mechanism of action really matter? CNS Drugs. 2011;25(11):907\u201312.","journal-title":"CNS Drugs"},{"issue":"2","key":"21_CR6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/11584860-000000000-00000","volume":"25","author":"LJ Stephen","year":"2011","unstructured":"Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs. 2011;25(2):89\u2013107.","journal-title":"CNS Drugs"},{"issue":"10","key":"21_CR7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1056\/NEJMra1004418","volume":"365","author":"P Kwan","year":"2011","unstructured":"Kwan P, Schachter SC, Brodie MJ. Current concepts: drug-resistant epilepsy. N Engl J Med. 2011;365(10):919\u201326.","journal-title":"N Engl J Med"},{"issue":"10","key":"21_CR8","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/jnnp.2004.045690","volume":"75","author":"P Kwan","year":"2004","unstructured":"Kwan P, Sander JW. The natural history of epilepsy: an epidemiological view. J Neurol Neurosurg Psychiatry. 2004;75(10):1376\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"21_CR9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.yebeh.2008.10.013","volume":"14","author":"JO Elliott","year":"2009","unstructured":"Elliott JO, Lu B, Shneker B, et al. Comorbidity, health screening, and quality of life among persons with a history of epilepsy. Epilepsy Behav. 2009;14(1):125\u20139.","journal-title":"Epilepsy Behav"},{"key":"21_CR10","unstructured":"European Medicines Agency. Fycompa (perampanel) film-coated tablet: summary of product characteristics. 2012. http:\/\/www.ema.europa.eu\/docs . Accessed 2012 Sept 6."},{"issue":"7","key":"21_CR11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","volume":"52","author":"T Hanada","year":"2011","unstructured":"Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia. 2011;52(7):1331\u201340.","journal-title":"Epilepsia"},{"issue":"4","key":"21_CR12","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s11910-007-0053-z","volume":"7","author":"HE Scharfman","year":"2007","unstructured":"Scharfman HE. The neurobiology of epilepsy. Curr Neurol Neurosci Rep. 2007;7(4):348\u201354.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"8861","key":"21_CR13","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/0140-6736(93)90754-5","volume":"341","author":"MJ During","year":"1993","unstructured":"During MJ, Spencer DD. Extracellular hippocampal glutamate and spontaneous seizure in the conscious human brain. Lancet. 1993;341(8861):1607\u201310.","journal-title":"Lancet"},{"issue":"1","key":"21_CR14","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.nurt.2006.11.010","volume":"4","author":"BS Meldrum","year":"2007","unstructured":"Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics. 2007;4(1):18\u201361.","journal-title":"Neurotherapeutics"},{"key":"21_CR15","doi-asserted-by":"crossref","unstructured":"Meldrum BS. Glutamate as a neurotransmitter in the brain: review of physiology and pathology. J Nutr. 2000;130(4S Suppl):1007S\u201315S.","DOI":"10.1093\/jn\/130.4.1007S"},{"issue":"2","key":"21_CR16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5698\/1535-7511-11.2.56","volume":"11","author":"MA Rogawski","year":"2011","unstructured":"Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11(2):56\u201363.","journal-title":"Epilepsy Curr"},{"issue":"4","key":"21_CR17","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.neuint.2012.02.035","volume":"61","author":"L Ceolin","year":"2012","unstructured":"Ceolin L, Bortolotto ZA, Bannister N, et al. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int. 2012;61(4):517\u201322.","journal-title":"Neurochem Int"},{"key":"21_CR18","unstructured":"Hussein Z, Ferry J, Krauss G, et al. Demographic factors and concomitant antiepileptic drugs have no effect on the pharmacodynamics of perampanel [abstract no. P06.127]. 64th Annual Meeting of the American Academy of Neurology, New Orleans (LA); 21\u201328 Apr 2012."},{"issue":"Suppl. 6","key":"21_CR19","first-page":"248","volume":"52","author":"Z Hussein","year":"2011","unstructured":"Hussein Z, Critchley D, Ferry J, et al. Population pharmacokinetics of perampanel, a selective, noncompetitive AMPA receptor antagonist, in patients with refractory partial-onset seizures participating in a randomized, double-blind, placebo-controlled phase III study [abstract no. p821]. Epilepsia. 2011;52(Suppl. 6):248\u20139.","journal-title":"Epilepsia"},{"key":"21_CR20","unstructured":"Fycompa (perampanel) US prescribing information. 2012. http:\/\/us.eisai.com\/package_inserts\/FycompaPI.pdf . Accessed Oct 24 2012."},{"key":"21_CR21","unstructured":"Templeton D. Pharmacokinetics of perampanel, a highly selective ampa-type glutamate receptor antagonist [abstract no. 1.199]. 63rd Annual Meeting of the American Epilepsy Society, Boston (MA); 4\u20138 Dec 2009."},{"key":"21_CR22","unstructured":"Laurenza A, Ferry J, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials [abstract no. 2.231 plus poster]. 65th Annual Meeting of the American Epilepsy Society, Baltimore (MD); 2\u20136 Dec 2011."},{"issue":"6","key":"21_CR23","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","volume":"79","author":"JA French","year":"2012","unstructured":"French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79(6):589\u201396.","journal-title":"Neurology"},{"key":"21_CR24","doi-asserted-by":"crossref","unstructured":"French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305. Epilepsia Epub. 2012 Aug 22.","DOI":"10.1111\/j.1528-1167.2012.03638.x"},{"issue":"18","key":"21_CR25","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","volume":"78","author":"GL Krauss","year":"2012","unstructured":"Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78(18):1408\u201315.","journal-title":"Neurology"},{"issue":"1","key":"21_CR26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.2011.01588.x","volume":"125","author":"GL Krauss","year":"2012","unstructured":"Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand. 2012;125(1):8\u201315.","journal-title":"Acta Neurol Scand"},{"key":"21_CR27","doi-asserted-by":"crossref","unstructured":"Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307. Epilepsia Epub. 2012 Aug 22.","DOI":"10.1111\/j.1528-1167.2012.03648.x"},{"issue":"Suppl. 5","key":"21_CR28","first-page":"190","volume":"53","author":"E Ben-Menachem","year":"2012","unstructured":"Ben-Menachem E, Krauss GL, Noachtar S, et al. Efficacy and safety of once-daily adjunctive perampanel, a selective AMPA antagonist: a pooled analysis of three phase III trials in patients with treatment-resistant partial-onset seizures [abstract no. p656]. Epilepsia. 2012;53(Suppl. 5):190\u20131.","journal-title":"Epilepsia"},{"key":"21_CR29","unstructured":"Krauss G, Perucca E, Brodie M, et al. Pooled analysis of responder rates and seizure freedom from phase III clinical trials of adjunctive perampanel, a selective, non-competitive AMPA receptor antagonist [abstract no. PD3.010]. 64th Annual Meeting of the American Academy of Neurology, New Orleans (LA); 21\u201328 April 2012."},{"issue":"Suppl. 5","key":"21_CR30","first-page":"122","volume":"53","author":"BJ Steinhoff","year":"2012","unstructured":"Steinhoff BJ, Gauffin H, Mckee P, et al. Efficacy of perampanel, a selective AMPA antagonist, in complex partial and secondarily generalized seizures: a pooled analysis of phase III studies in patients with treatment-resistant partial-onset seizures [abstract no. p417]. Epilepsia. 2012;53(Suppl. 5):122.","journal-title":"Epilepsia"},{"key":"21_CR31","doi-asserted-by":"crossref","unstructured":"Kramer L, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, non-competitive AMPA receptor antagonist as adjunctive therapy in patients with refractory partial-onset seizures: a dose response analysis from phase III studies [abstract no. P06.117]. 64th Annual Meeting of the American Academy of Neurology, New Orleans (LA); 21\u201328 Apr 2012.","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.P06.117"},{"issue":"Suppl. 5","key":"21_CR32","first-page":"194","volume":"53","author":"E Trinka","year":"2012","unstructured":"Trinka E, Straub H, Squillacote D, et al. Analysis of seizure frequency reduction by concomitant antiepileptic drug (AED) use with adjunctive perampanel: pooled phase III results [abstract no. p669]. Epilepsia. 2012;53(Suppl. 5):194\u20135.","journal-title":"Epilepsia"},{"key":"21_CR33","doi-asserted-by":"crossref","unstructured":"Laurenza A, French J, Gil-Nagel A, et al. Perampanel, a selective, non-competitive AMPA receptor antagonist, prolongs time to seizure recurrence in patients with epilepsy: results of pooled phase III clinical trial data [abstract no. S56.005]. 64th Annual Meeting of the American Academy of Neurology, New Orleans (LA); 21\u201328 Apr 2012.","DOI":"10.1212\/WNL.78.1_MeetingAbstracts.S56.005"},{"issue":"Suppl. 6","key":"21_CR34","first-page":"242","volume":"52","author":"V Villanueva","year":"2011","unstructured":"Villanueva V, Rozentals G, Yang H, et al. Efficacy and safety of perampanel as adjunctive therapy in adolescents with refractory partial-onset seizures: analysis of a randomized, double-blind, placebocontrolled phase III study [abstract no. p799]. Epilepsia. 2011;52(Suppl. 6):242.","journal-title":"Epilepsia"},{"issue":"Suppl. 5","key":"21_CR35","first-page":"52","volume":"53","author":"GL Krauss","year":"2012","unstructured":"Krauss GL, Kerling F, Villanueva V, et al. Drug resistance and seizure severity of patients in partial-onset seizure registration trials of perampanel compared with recently approved antiepileptic drugs [abstract no. p176]. Epilepsia. 2012;53(Suppl. 5):52\u20133.","journal-title":"Epilepsia"},{"issue":"4","key":"21_CR36","first-page":"263","volume":"126","author":"I Rektor","year":"2012","unstructured":"Rektor I, Krauss GL, Bar M, et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand. 2012;126(4):263\u20139.","journal-title":"Acta Neurol Scand"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-012-0021-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-012-0021-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-012-0021-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,7]],"date-time":"2019-07-07T04:27:35Z","timestamp":1562473655000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-012-0021-2"}},"subtitle":["As Adjunctive Therapy in Patients with Partial-Onset Seizures"],"short-title":[],"issued":{"date-parts":[[2012,11,23]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["21"],"URL":"https:\/\/doi.org\/10.1007\/s40263-012-0021-2","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,11,23]]}}}